Skip to main content

Glabellar Frown Lines

17
Pipeline Programs
6
Companies
17
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
9
5
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Ipsen
DYSPORTApproved
botulinum toxin type a
Ipsen
Acetylcholine Release Inhibitor [EPC]injection2009
3M Part D

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Galderma
GaldermaTX - Dallas
9 programs
2
4
3
AbobotulinumtoxinAPhase 41 trial
AlluziencePhase 41 trial
AzzalurePhase 41 trial
AbobotulinumtoxinAPhase 31 trial
QM1114-DPPhase 31 trial
+4 more programs
Active Trials
NCT03736928Completed401Est. Aug 2020
NCT02236312Completed359Est. May 2015
NCT03960957Completed301Est. Apr 2020
+6 more trials
AbbVie
AbbVieNORTH CHICAGO, IL
2 programs
1
1
botulinum toxin Type APhase 41 trial
OnabotulinumtoxinAPhase 11 trial
Active Trials
NCT05083286Unknown40Est. Aug 2022
NCT01391312Completed40Est. Oct 2011
Ipsen
IpsenChina - Tianjin
1 program
1
Botulinum toxin type APHASE_21 trial
Active Trials
NCT01333397Completed176Est. Sep 2011
Croma-Pharma
Croma-PharmaAustria - Leobendorf
3 programs
3
Botulinum Toxin APhase 31 trial
Botulinum Toxin APhase 31 trial
Botulinum Toxin APhase 31 trial
Active Trials
NCT02677805Completed251Est. Nov 2017
NCT02677298Completed784Est. Nov 2017
NCT03985982Completed410Est. Dec 2020
EuBiologics
EuBiologicsKorea - Seoul
1 program
1
ATGC-100 100UPhase 31 trial
Active Trials
NCT04830345Completed290Est. Oct 2021
Huons
HuonsKorea - Seongnam
1 program
1
Hutox InjPhase 31 trial
Active Trials
NCT03440671Unknown260Est. Dec 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GaldermaAlluzience
GaldermaAbobotulinumtoxinA
GaldermaAzzalure
AbbViebotulinum toxin Type A
GaldermaQM1114-DP
GaldermaQM1114-DP
EuBiologicsATGC-100 100U
Galdermabotulinum toxin
GaldermaAbobotulinumtoxinA
Croma-PharmaBotulinum Toxin A
HuonsHutox Inj
Croma-PharmaBotulinum Toxin A
Croma-PharmaBotulinum Toxin A
GaldermaAbobotulinumtoxinA dose level 1 or 2
GaldermaBotulinum Toxin Type A

Showing 15 of 17 trials with date data

Clinical Trials (17)

Total enrollment: 4,101 patients across 17 trials

Study Comparing Treatment With Alluzience vs Reconstituted Toxin

Start: Feb 2022Est. completion: Oct 2022150 patients
Phase 4Completed
NCT03687736GaldermaAbobotulinumtoxinA

Subject Satisfaction With AbobutulinumtoxinA Treatment

Start: Oct 2018Est. completion: Dec 2019120 patients
Phase 4Completed

A Safety and Efficacy Study of Different Injections Volumes of Botulinum Toxin Type A, Azzalure, in the Glabellar Lines

Start: Apr 2014Est. completion: Dec 201462 patients
Phase 4Completed
NCT01391312AbbViebotulinum toxin Type A

Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines

Start: Jun 2011Est. completion: Oct 201140 patients
Phase 4Completed

Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines

Start: Jan 2023Est. completion: Jun 202325 patients
Phase 3Completed

Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines

Start: May 2022Est. completion: Sep 2023132 patients
Phase 3Completed

Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines

Start: Jun 2020Est. completion: Oct 2021290 patients
Phase 3Completed
NCT04249583Galdermabotulinum toxin

Treatment of Moderate to Severe Glabellar Lines

Start: Feb 2020Est. completion: Jan 2021300 patients
Phase 3Completed
NCT03960957GaldermaAbobotulinumtoxinA

Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines

Start: Jun 2019Est. completion: Apr 2020301 patients
Phase 3Completed
NCT03985982Croma-PharmaBotulinum Toxin A

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)

Start: Apr 2019Est. completion: Dec 2020410 patients
Phase 3Completed

The Safety and Efficacy Study of Hutox Versus Botox® in Subject With Moderate to Severe Glabellar Lines

Start: Nov 2017Est. completion: Dec 2018260 patients
Phase 3Unknown
NCT02677805Croma-PharmaBotulinum Toxin A

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II

Start: Mar 2016Est. completion: Nov 2017251 patients
Phase 3Completed
NCT02677298Croma-PharmaBotulinum Toxin A

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I

Start: Mar 2016Est. completion: Nov 2017784 patients
Phase 3Completed
NCT03736928GaldermaAbobotulinumtoxinA dose level 1 or 2

Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines

Start: Nov 2018Est. completion: Aug 2020401 patients
Phase 2Completed
NCT02236312GaldermaBotulinum Toxin Type A

Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines

Start: Sep 2014Est. completion: May 2015359 patients
Phase 2Completed
NCT01333397IpsenBotulinum toxin type A

Safety and Efficacy Study of Dysport RU and Glabellar Lines

Start: Mar 2011Est. completion: Sep 2011176 patients
Phase 2Completed
NCT05083286AbbVieOnabotulinumtoxinA

Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines

Start: Oct 2021Est. completion: Aug 202240 patients
Phase 1Unknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

9 late-stage (Phase 3) programs, potential near-term approvals
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.